Audentes Therapeutics (BOLD)

39.55 +0.65 (1.67%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (5/9/19 *Est.)

Latest Headlines

Audentes Therapeutics (BOLD) PT Raised to $48 at SVB Leerink April 17, 2019 6:23 AM - StreetInsider Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in April 15, 2019 4:01 PM - PR NewsWire Audentes Therapeutics (BOLD) PT Raised to $57 at Wedbush April 9, 2019 6:46 AM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $55 at Piper Jaffray April 8, 2019 3:46 PM - StreetInsider Form 8-K Audentes Therapeutics, For: Apr 08 April 8, 2019 7:12 AM - SEC Filing Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy April 8, 2019 7:00 AM - PR NewsWire Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 5, 2019 6:00 PM - PR NewsWire Form 4 Audentes Therapeutics, For: Mar 28 Filed by: Meltz Mark A April 1, 2019 5:55 PM - SEC Filing Form 3 Audentes Therapeutics, For: Mar 28 Filed by: Meltz Mark A April 1, 2019 5:54 PM - SEC Filing Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer April 1, 2019 8:00 AM - PR NewsWire NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Establishing Itself as a Trailblazer in Breakthrough Cancer Treatments March 29, 2019 9:00 AM - StreetInsider Form 4 Audentes Therapeutics, For: Mar 25 Filed by: LANGE LOUIS G March 27, 2019 5:04 PM - SEC Filing Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy March 27, 2019 9:00 AM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $44 at H.C. Wainwright March 18, 2019 7:39 AM - StreetInsider Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 8, 2019 6:00 PM - PR NewsWire Form 10-K Audentes Therapeutics, For: Dec 31 March 1, 2019 5:19 PM - SEC Filing Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases February 28, 2019 8:03 AM - PR NewsWire Audentes Therapeutics (BOLD) PT Raised to $45 at Piper Jaffray February 28, 2019 6:32 AM - StreetInsider Form 4 Audentes Therapeutics, For: Feb 25 Filed by: PRASAD SUYASH February 27, 2019 4:35 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 25 Filed by: Patterson Matthew R February 27, 2019 4:34 PM - SEC Filing Audentes Therapeutics (BOLD) Tops Q4 EPS by 8c February 27, 2019 4:22 PM - StreetInsider Form 8-K Audentes Therapeutics, For: Feb 27 February 27, 2019 4:22 PM - SEC Filing Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update February 27, 2019 4:01 PM - PR NewsWire Pre-Open Stock Movers 02/25: (ONCE) (CMTA) (QURE) Higher; (MDR) (CRON) (NBR) Lower (more...) February 25, 2019 9:25 AM - StreetInsider Chardan Capital Markets Upgrades Audentes Therapeutics (BOLD) to Buy February 24, 2019 9:23 PM - StreetInsider Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019 February 21, 2019 8:01 AM - PR NewsWire Audentes Therapeutics to Participate in Upcoming Investor Conferences February 20, 2019 8:01 AM - PR NewsWire Form SC 13G/A Audentes Therapeutics, Filed by: Partner Fund Management, L.P. February 14, 2019 5:26 PM - SEC Filing Form SC 13G Audentes Therapeutics, Filed by: Redmile Group, LLC February 14, 2019 4:16 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/ February 14, 2019 2:09 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: 5AM VENTURES III, L.P. February 13, 2019 4:23 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: FMR LLC February 13, 2019 11:50 AM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: ORBIMED ADVISORS LLC February 13, 2019 6:14 AM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP February 12, 2019 9:43 AM - SEC Filing Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 8, 2019 6:00 PM - PR NewsWire Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Patterson Matthew R February 8, 2019 5:51 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Soloway Thomas P February 8, 2019 5:30 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Smith Julie February 8, 2019 5:29 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Schuetz Thomas J. February 8, 2019 5:28 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: PRASAD SUYASH February 8, 2019 5:26 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Morrison Scott W February 8, 2019 5:25 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: LANGE LOUIS G February 8, 2019 5:23 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Jarrett Jennifer February 8, 2019 5:23 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Holles Natalie C. February 8, 2019 5:22 PM - SEC Filing Form 4 Audentes Therapeutics, For: Feb 06 Filed by: Goldberg Mark Alan February 8, 2019 5:21 PM - SEC Filing Form SC 13G Audentes Therapeutics, Filed by: BlackRock Inc. February 8, 2019 6:14 AM - SEC Filing Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation January 31, 2019 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Jan 24 Filed by: Holles Natalie C. January 25, 2019 7:29 PM - SEC Filing Full Article List